Urothelial carcinoma ureter metastatic

Also known as: Metastatic Urothelial Carcinoma / Metastatic urothelial cell carcinoma / Malignant neoplasm of ureter metastatic / Ureter cancer metastatic / Ureteric cancer metastatic

DrugDrug NameDrug Description
DB11595AtezolizumabAtezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy.[L7489] Atezolizumab was granted FDA approval on 18 October 2016.[L7489]
DB11714DurvalumabDurvalumab is a a human monoclonal antibody that blocks programmed death ligand 1 (PD-L1), or CD 274. In May, 2017 it received FDA approval for previously treated patients with locally advanced or metastatic cancer in the urinary system (as Imfinzi). It is shown to be effective in patients with continued disease progression after the platinum-based chemotherapy. This drug has a relatively tolerable safety profile and its structural modification advantageously prevents the induction of antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) [L749].
DB09037PembrolizumabPembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing S228P Fc mutation.[A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds.[F136] It was developed by Merck & Co and firstly approved for the treatment of metastatic malignant melanoma. This is the first approved therapy against PD-1.[A7624] It was approved firstly by the FDA on September 4, 2014.[L2954] Its approval in melanoma was extended to several countries such as Australia, Israel, Korea, Macau, the European Union and the United Arab Emirates.[A33350] On June 12, 2018, Pembrolizumab was approved for the treatment of cervical cancer under the status of accelerated approval.[L2955]
DB00642PemetrexedPemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated.
DrugDrug NamePhaseStatusCount
DB12565Abexinostat1Recruiting1
DB00112Bevacizumab1Recruiting1
DB00002Cetuximab1Recruiting1
DB09037Pembrolizumab1Not Yet Recruiting1
DB09037Pembrolizumab1Recruiting1
DB09143Sonidegib1Not Yet Recruiting1
DB06287Temsirolimus1Recruiting1
DB00313Valproic acid1Recruiting1
DB08871Eribulin1 / 2Active Not Recruiting1
DB09037Pembrolizumab1 / 2Recruiting1
DB12887Tazemetostat1 / 2Recruiting1
DB11595Atezolizumab2Recruiting2
DB11595Atezolizumab2Suspended1
DB11945Avelumab2Recruiting1
DB08875Cabozantinib2Recruiting1
DB00958Carboplatin2Not Yet Recruiting1
DB14917Ceralasertib2Recruiting1
DB08871Eribulin2Suspended1
DB00441Gemcitabine2Not Yet Recruiting1
DB09035Nivolumab2Recruiting2
DB09074Olaparib2Recruiting2
DB09037Pembrolizumab2Active Not Recruiting1
DB09037Pembrolizumab2Not Yet Recruiting2
DB09037Pembrolizumab2Recruiting1
DB00642Pemetrexed2Active Not Recruiting1
DB00642Pemetrexed2Recruiting1
DB15102Pemigatinib2Not Yet Recruiting1
DB12332Rucaparib2Recruiting2
DB11836Sapanisertib2Recruiting1
DB00112Bevacizumab3Active Not Recruiting1
DB00515Cisplatin3Active Not Recruiting1
DB00441Gemcitabine3Active Not Recruiting1
DB12117Mitometh3Active Not Recruiting1
DB12257Platinum3Active Not Recruiting1